id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-348501-8cvtqj7w	Beyzaee, Amir Mohammad	Rituximab as the treatment of pemphigus vulgaris in the COVID‐19 pandemic era: A narrative review	2020-10-20		.txt	text/plain	2510	145	41	As the immunosuppressive effect of rituximab, the first‐line therapy of PV, lasts more than 6 months, many concerns have raised due to the ongoing novel coronavirus disease (COVID‐19) pandemic. We performed a computer-assisted search of "PubMed" and "Google Scholar" databases up to 14 July 2020 using the keywords "anti-CD20 therapy," "pemphigus vulgaris," and "COVID-19." We also searched other related keywords such as coronavirus, rituximab, immunocompromised, immunosuppressive drugs, pathogenesis, clinical presentations, treatment, and outcome. 17, 18 Athough some studies may have reported that risk of infections is not different between AIBD patients treated with rituximab or high dose corticosteroids, 16 Coronavirus can target the central nervous system (CNS), which is protected by humoral immunity. 31 Also, Guilpain et al reported three systemic sclerosis (SSc) patients treating with rituximab, which resulted to late clinical worsening to severe pneumonia due to the COVID-19 infection.	./cache/cord-348501-8cvtqj7w.txt	./txt/cord-348501-8cvtqj7w.txt